284 related articles for article (PubMed ID: 22552254)
1. Propranolol as antiangiogenic candidate for the therapy of hereditary haemorrhagic telangiectasia.
Albiñana V; Recio-Poveda L; Zarrabeitia R; Bernabéu C; Botella LM
Thromb Haemost; 2012 Jul; 108(1):41-53. PubMed ID: 22552254
[TBL] [Abstract][Full Text] [Related]
2. Estrogen therapy for hereditary haemorrhagic telangiectasia (HHT): Effects of raloxifene, on Endoglin and ALK1 expression in endothelial cells.
Albiñana V; Bernabeu-Herrero ME; Zarrabeitia R; Bernabéu C; Botella LM
Thromb Haemost; 2010 Mar; 103(3):525-34. PubMed ID: 20135064
[TBL] [Abstract][Full Text] [Related]
3. Hereditary hemorrhagic telangiectasia, a vascular dysplasia affecting the TGF-beta signaling pathway.
Fernández-L A; Sanz-Rodriguez F; Blanco FJ; Bernabéu C; Botella LM
Clin Med Res; 2006 Mar; 4(1):66-78. PubMed ID: 16595794
[TBL] [Abstract][Full Text] [Related]
4. Endoglin and alk1 as therapeutic targets for hereditary hemorrhagic telangiectasia.
Ruiz-Llorente L; Gallardo-Vara E; Rossi E; Smadja DM; Botella LM; Bernabeu C
Expert Opin Ther Targets; 2017 Oct; 21(10):933-947. PubMed ID: 28796572
[TBL] [Abstract][Full Text] [Related]
5. Immunosuppressor FK506 increases endoglin and activin receptor-like kinase 1 expression and modulates transforming growth factor-β1 signaling in endothelial cells.
Albiñana V; Sanz-Rodríguez F; Recio-Poveda L; Bernabéu C; Botella LM
Mol Pharmacol; 2011 May; 79(5):833-43. PubMed ID: 21310938
[TBL] [Abstract][Full Text] [Related]
6. Global gene expression profiling of telangiectasial tissue from patients with hereditary hemorrhagic telangiectasia.
Tørring PM; Larsen MJ; Kjeldsen AD; Ousager LB; Tan Q; Brusgaard K
Microvasc Res; 2015 May; 99():118-26. PubMed ID: 25892364
[TBL] [Abstract][Full Text] [Related]
7. TGF-β & BMP receptors endoglin and ALK1: overview of their functional role and status as antiangiogenic targets.
Jonker L
Microcirculation; 2014 Feb; 21(2):93-103. PubMed ID: 25279424
[TBL] [Abstract][Full Text] [Related]
8. Hereditary haemorrhagic telangiectasia: a rare disease as a model for the study of human atherosclerosis.
Lenato GM; Suppressa P; Giordano P; Guanti G; Guastamacchia E; Triggiani V; Amati L; Resta F; Covelli V; Jirillo E; Sabbà C
Curr Pharm Des; 2007; 13(36):3656-64. PubMed ID: 18220803
[TBL] [Abstract][Full Text] [Related]
9. Bazedoxifene, a new orphan drug for the treatment of bleeding in hereditary haemorrhagic telangiectasia.
Zarrabeitia R; Ojeda-Fernandez L; Recio L; Bernabéu C; Parra JA; Albiñana V; Botella LM
Thromb Haemost; 2016 Jun; 115(6):1167-77. PubMed ID: 26818701
[TBL] [Abstract][Full Text] [Related]
10. Hereditary haemorrhagic telangiectasia: current views on genetics and mechanisms of disease.
Abdalla SA; Letarte M
J Med Genet; 2006 Feb; 43(2):97-110. PubMed ID: 15879500
[TBL] [Abstract][Full Text] [Related]
11. Hereditary hemorrhagic telangiectasia: clinical features in ENG and ALK1 mutation carriers.
Sabbà C; Pasculli G; Lenato GM; Suppressa P; Lastella P; Memeo M; Dicuonzo F; Guant G
J Thromb Haemost; 2007 Jun; 5(6):1149-57. PubMed ID: 17388964
[TBL] [Abstract][Full Text] [Related]
12. Hereditary haemorrhagic telangiectasia: a questionnaire based study to delineate the different phenotypes caused by endoglin and ALK1 mutations.
Berg J; Porteous M; Reinhardt D; Gallione C; Holloway S; Umasunthar T; Lux A; McKinnon W; Marchuk D; Guttmacher A
J Med Genet; 2003 Aug; 40(8):585-90. PubMed ID: 12920067
[TBL] [Abstract][Full Text] [Related]
13. Mutation study of Spanish patients with hereditary hemorrhagic telangiectasia and expression analysis of Endoglin and ALK1.
Fernandez-L A; Sanz-Rodriguez F; Zarrabeitia R; Perez-Molino A; Morales C; Restrepo CM; Ramirez JR; Coto E; Lenato GM; Bernabeu C; Botella LM
Hum Mutat; 2006 Mar; 27(3):295. PubMed ID: 16470589
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic action of tranexamic acid in hereditary haemorrhagic telangiectasia (HHT): regulation of ALK-1/endoglin pathway in endothelial cells.
Fernandez-L A; Garrido-Martin EM; Sanz-Rodriguez F; Ramirez JR; Morales-Angulo C; Zarrabeitia R; Perez-Molino A; Bernabéu C; Botella LM
Thromb Haemost; 2007 Feb; 97(2):254-62. PubMed ID: 17264955
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of Activin Receptor-Like Kinase 1 in Endothelial Cells Suppresses Development of Arteriovenous Malformations in Mouse Models of Hereditary Hemorrhagic Telangiectasia.
Hwan Kim Y; Vu PN; Choe SW; Jeon CJ; Arthur HM; Vary CPH; Lee YJ; Oh SP
Circ Res; 2020 Oct; 127(9):1122-1137. PubMed ID: 32762495
[TBL] [Abstract][Full Text] [Related]
16. Blood outgrowth endothelial cells from Hereditary Haemorrhagic Telangiectasia patients reveal abnormalities compatible with vascular lesions.
Fernandez-L A; Sanz-Rodriguez F; Zarrabeitia R; Pérez-Molino A; Hebbel RP; Nguyen J; Bernabéu C; Botella LM
Cardiovasc Res; 2005 Nov; 68(2):235-48. PubMed ID: 15993872
[TBL] [Abstract][Full Text] [Related]
17. Propanolol and angiogenesis inhibition in hereditary haemorrhagic telangiectasia.
Breier G
Thromb Haemost; 2012 Jul; 108(1):1-2. PubMed ID: 22628061
[No Abstract] [Full Text] [Related]
18. Endoglin and activin receptor-like kinase 1 heterozygous mice have a distinct pulmonary and hepatic angiogenic profile and response to anti-VEGF treatment.
Ardelean DS; Jerkic M; Yin M; Peter M; Ngan B; Kerbel RS; Foster FS; Letarte M
Angiogenesis; 2014 Jan; 17(1):129-46. PubMed ID: 24061911
[TBL] [Abstract][Full Text] [Related]
19. Hereditary Haemorrhagic Telangiectasia (HHT): genetic and molecular aspects.
Lenato GM; Guanti G
Curr Pharm Des; 2006; 12(10):1173-93. PubMed ID: 16611099
[TBL] [Abstract][Full Text] [Related]
20. Reduced plasma levels of Ang-2 and sEng as novel biomarkers in hereditary hemorrhagic telangiectasia (HHT).
Ojeda-Fernandez L; Barrios L; Rodriguez-Barbero A; Recio-Poveda L; Bernabeu C; Botella LM
Clin Chim Acta; 2010 Apr; 411(7-8):494-9. PubMed ID: 20067780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
